Insulin tregopil

Drug Profile

Insulin tregopil

Alternative Names: GW 843362; Hexyl Insulin M2; Hexyl insulin monoconjugate 2; HIM2; IN-105; NIN-058; Oral prandial insulin - Biocon

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nobex Corporation
  • Developer Biocon; Bristol-Myers Squibb
  • Class Antihyperglycaemics; Hormones; Insulins; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 06 Sep 2017 Biocon and JDRF agree to co-develop Insulin tregopil for Type-1-diabetes (http://www.biocon.com/docs/Biocon_Annual_Report_2017.pdf)
  • 22 Aug 2017 Insulin tregopil is still at phase I/II development stage for Type-1 diabetes mellitus and Type-2 diabetes mellitus in USA (PO)
  • 27 Apr 2017 Biocon, in collaboration with Juvenile Diabetes Research foundation, plans a multiple ascending dose clinical trial for Type-1 diabetes mellitus in Europe (PO) in FY 2018 (Biocon Annual Report 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top